MeMed
At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. MeMed BV is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes. MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute infections and suspected sepsis. MeMed Severity is not yet cleared for sale in any territory.Content by MeMed
| 2 min read
Real-world data and KOL insights highlight MeMed BV’s supportive role in emergency medicine
Page 1 of 1 - 1 Total Items
